Evidence map›Paper›PMID 38547457›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2025

Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women.

Intira Sriprasert, Stephanie S Kim, Iram Elias Mohammed, Naoko Kono, Roksana Karim, Hooman Allayee, Howard N Hodis, Wendy J Mack, Ronald M Krauss

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Intira SriprasertDepartment of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA 90033, USA.ORCID 0000-0001-5367-762X
Stephanie S KimDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Iram Elias MohammedDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Naoko KonoDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Roksana KarimDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Hooman AllayeeDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.ORCID 0000-0002-2384-5239
Howard N HodisDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Wendy J MackDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032, USA.
Ronald M KraussUniversity of California, San Francisco, CA 94143, USA.
University of Southern California · USUniversity of California, San Francisco · US

Funding

Biologic Response of Menopausal Women to 17B-EstradiolR01AG024154 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HODIS, HOWARD NEIL · 2004 to 2012
$13.8M
MECHANISMS UNDERLYING THE AGE-RELATED ATHEROPROTECTIVE EFFECTS OF HORMONE THERAPYR01AG059690 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HODIS, HOWARD NEIL · 2018 to 2022
$3.6M
NIA NIH HHS R01 AG024154NIA NIH HHS R01 AG059690NIH HHS R01-AG024154
6 · The paper itself

Abstract

contextThe Early vs Late Intervention Trial with Estradiol (ELITE) showed that hormone therapy (HT) reduced atherosclerosis progression among early but not late postmenopausal women (PMW).

objectiveDetermined by time-since-menopause (1) HT effects on lipids and lipoprotein particle subfractions (LPs), (2) associations of estradiol (E2) level with lipids and LPs, (3) associations of lipids and LPs with atherosclerosis progression.

designRandomized controlled trial stratified by time-since-menopause.

settingAcademic institution.

participantsHealthy postmenopausal women.

interventionOral E2 with/without sequential vaginal progesterone.

main outcome measuresStandard lipids and 21 LPs quantitated by ion mobility every 6 months.

resultsAmong 562 PMW (240 early, 322 late), HT significantly increased total triglycerides (TG), high-density lipoprotein (HDL) cholesterol, small low-density lipoproteins (LDL), large HDL, and TG/C ratio in LDL and HDL and decreased LDL-cholesterol, total very low density lipoproteins (VLDL), small VLDL, intermediate-density lipoproteins, large LDL, and LDL peak diameter. HT showed no lipid or LP differences between time-since-menopause. Associations of E2 level with lipids and LPs explained the HT effects. Despite the nonsignificant P interaction by time-since-menopause, we observed that very small LDL and total HDL LPs were associated with atherosclerosis progression in late PMW.

conclusionHT effects on standard lipids and LPs are consistent with the literature. HT has similar effect on lipids and LPs in early and late PMW. Novel findings include discordant effects of HT on TG and VLDL particles, which can be explained by increased catabolism of atherogenic remnants of TG-rich lipoproteins. Our findings extend the well-known HT effects on standard lipids and LPs that may contribute to the beneficial effects on atherosclerosis progression in PMW.

Indexed as

EstradiolEstrogen Replacement TherapyLipoproteinsPostmenopauseAgedAtherosclerosisFemaleHumansMiddle AgedProgesteroneTriglyceridesEstradiolLipoproteinsProgesteroneTriglyceridesatherosclerosisestrogenhormone therapylipidslipoproteinsmenopause

Identifiers

PMID38547457
PMCPMC11747678
OpenAlexW4393320053

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.